NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT04055428

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04055428
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04055428. Randomized; quadruple masking; primary purpose treatment. Start 2020-08-15 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
Condition
Diabetes Mellitus
Condition
Cardiovascular Diseases
Condition
Insulin Sensitivity/Resistance
Condition
Metabolic Disease
Condition
Metabolism
Condition
Energy Expenditure
Intervention (Drug)
Sacubitril, Valsartan 97-103 mg Oral Tablet
Intervention (Drug)
Valsartan 160 mg
Intervention (Other)
Intravenous Glucose Tolerance Test
Intervention (Dietary supplement)
Standardized Meals
Intervention (Other)
Exercise capacity VO2 maximum determination
Lead sponsor
University of Alabama at Birmingham (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct04055428
Content hash
ecf4687421f105b9db0ecf78fa5e9627891f30c3b7f1ea9eaa158f00aacea928